Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of effectively treating nephritis, comprising:

selecting an animal in need of treatment for nephritis; and

administering to said animal a therapeutically effective dose of a neutralizing antibody, or binding fragment thereof, that binds to platelet derived growth factor-DD (PDGF-DD),

wherein said neutralizing antibody, or binding fragment thereof, neutralizes PDGF-DD-induced mitogenic activity, and wherein said neutralizing antibody, or binding fragment thereof, comprises ~~cross-reacts with~~ fully human anti-PDGF-DD antibody mAb 6.4 or an antibody in the same antigen-binding bin as fully human anti-PDGF-DD antibody mAb 6.4 selected from fully human antibody mAb 1.9, 1.19, 1.22, and 1.29, and wherein said nephritis is selected from mesangial proliferative nephritis, mesangial proliferative glomerulonephritis and glomerular nephritis.

2. (Original) The method of claim 1, wherein said animal is a human.

3. (Previously Presented) The method of claim 1, wherein said neutralizing antibody is a fully human monoclonal antibody.

4. - 5. (Cancelled)

6. (Original) The method of claim 1, wherein said administration is via subcutaneous injection.

7. (Original) The method of claim 1, wherein said administration is via intramuscular injection.

8. - 21. (Cancelled)

22. (Previously Presented) The method of claim 1, wherein said neutralizing antibody has a Kd in the range of about 10^{-6} to 10^{-11} M as measured in either solid phase or solution phase.

23. (Previously Presented) The method of claim 1, wherein said neutralizing antibody comprises a fully human IgG2 heavy chain.

24. (Previously Presented) The method of claim 1, wherein said neutralizing antibody comprises a fully human IgG2 heavy chain and a human kappa light chain.

25. (Currently Amended) A method of effectively treating nephritis, comprising:

selecting an animal in need of treatment for nephritis; and

administering to said animal a therapeutically effective dose of a neutralizing antibody, or binding fragment thereof, that binds to platelet derived growth factor-DD (PDGF-DD),

wherein said neutralizing antibody, or binding fragment thereof, neutralizes PDGF-DD-induced mitogenic activity, and wherein said neutralizing antibody, or binding fragment thereof comprises fully human anti-PDGF-DD antibody mAb 6.4 or an antibody in the same antigen-binding bin as fully human anti-PDGF-DD antibody mAb 6.4 selected from fully human antibody mAb 1.9, 1.19, 1.22, and 1.29 and wherein said neutralizing antibody, or binding fragment thereof, comprises a fully human IgG2 heavy chain, and wherein said nephritis is selected from mesangial proliferative nephritis, mesangial proliferative glomerulonephritis and glomerular nephritis.

26. (Previously Presented) The method of claim 25, wherein said neutralizing antibody further comprises a human kappa light chain.

27. (Previously Presented) The method of claim 25, wherein said animal is a human.

28. (Previously Presented) The method of claim 25, wherein said neutralizing antibody is a fully human monoclonal antibody.

29. - 30. (Cancelled)

31. (Previously Presented) The method of claim 25, wherein said administration is via subcutaneous injection.

32. (Previously Presented) The method of claim 25, wherein said administration is via intramuscular injection.

33. (Previously Presented) The method of claim 25, wherein said neutralizing antibody has a Kd in the range of about 10^{-6} to 10^{-11} M as measured in either solid phase or solution phase.